Cargando…
BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial
BACKGROUND AND PURPOSE: Dose-escalation in rectal cancer (RCa) may result in an increased complete response rate and thereby enable omission of surgery and organ preservation. In order to implement dose-escalation, it is crucial to develop a technique that allows for accurate image-guided radiothera...
Autores principales: | Opbroek, Thirza J.S., Willems, Yves C.P., Verhaegen, Frank, de Ridder, Rogier, Hoge, Chantal, Melenhorst, Jarno, Bakers, Frans, Grabsch, Heike I., Buijsen, Jeroen, Van Limbergen, Evert J., Canters, Richard A.M., Berbée, Maaike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668658/ https://www.ncbi.nlm.nih.gov/pubmed/36407490 http://dx.doi.org/10.1016/j.ctro.2022.10.013 |
Ejemplares similares
-
Evaluation of a Novel Liquid Fiducial Marker, BioXmark(®), for Small Animal Image-Guided Radiotherapy Applications
por: Brown, Kathryn H., et al.
Publicado: (2020) -
Focal salvage high-dose-rate brachytherapy with implantable rectum spacer for locally recurrent prostate cancer after initial low-dose-rate with grade 3 rectal toxicity
por: Opbroek, Thirza, et al.
Publicado: (2023) -
Prediction models for brachytherapy-induced rectal toxicity in patients with locally advanced pelvic cancers: a systematic review
por: Tohidinezhad, Fariba, et al.
Publicado: (2022) -
GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer
por: Stewart, Alexandra J., et al.
Publicado: (2021) -
Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients?
por: Vanneste, Ben G.L., et al.
Publicado: (2021)